Sign up for our Weekly Checkup Newsletter
Back to News
Insights · News

Cardinal Health's $235 million AdaptHealth diabetes deal reaches Oregon, with a February close in view

Cardinal Health's $235 million purchase of AdaptHealth's Diabetes Health business has reached Oregon regulators, with the filing pointing to a February 1, 2027 effective date.

7 min read

Cardinal Health's purchase of AdaptHealth's Diabetes Health business, announced in July at $235 million, surfaced on November 3, 2026 as the 97th transaction on the Oregon Health Authority's Health Care Market Oversight list, filed under the name of the Cardinal subsidiary that will own it, RGH Enterprises, LLC, better known as Edgepark. The Oregon notice fills in a good deal that the July announcement left out: the asset purchase agreement is dated July 19, 2026, the anticipated effective date is February 1, 2027, the federal antitrust waiting period expired on August 31 without a second request, and the business being sold is a group of seven AdaptHealth subsidiaries that together serve more than 225,000 people a year by mail.

What the filing says

The transaction is an asset purchase. RGH will acquire the assets of Pinnacle Medical Solutions, Diabetes Supply Center of the Midlands, Healthy Living Medical Supply, Diabetes Management and Supplies, J.M.R. Medical, Pal-Med and Solara Medical Supplies, the subsidiaries through which AdaptHealth distributes and dispenses continuous glucose monitors, insulin pumps and related supplies, for $235,000,000 subject to adjustment. At closing the parties will sign a transition services agreement priced at documented cost without markup. The selling subsidiaries stay with AdaptHealth until their remaining operations wind down, after which AdaptHealth will consolidate them. RGH will employ the general manager of the diabetes business after closing, and the filing says the deal will produce no workforce changes in Oregon.

The process section is more candid than most. AdaptHealth decided to divest the segment in January 2026 and engaged Deutsche Bank; after an initial bid from RGH the two sides moved to an exclusive negotiation, which the filing attributes to Cardinal's "strong strategic rationale and financial position." J.P. Morgan advised Cardinal; Skadden and DLA Piper were its counsel and Reed Smith represented AdaptHealth. Cardinal's diligence included a billing and coding audit, a quality of earnings and quality of revenue review and a clean room for competitively sensitive data.

Part of the rationale is technical. Edgepark is in the middle of moving its systems to a cloud platform that the AdaptHealth diabetes business already runs on, and the IT assets are included in the sale; the filing says Cardinal expects to migrate Edgepark onto the acquired systems rather than build new ones.

On regulatory status, the notice lists the HSR filing on July 30 and expiry on August 31, material change notices to the Massachusetts Health Policy Commission and the Indiana Attorney General on September 16, a contemporaneous HSR copy to the Washington Attorney General, and a New York Department of Health notice still to be filed, with board of pharmacy filings closer to closing. The Oregon review opened November 3 and the office is taking public comment.

The Oregon-specific figures are modest. Cardinal's at-Home Solutions segment has about 3,800 full-time equivalents nationally and 83 in Oregon, where its presence is a single distribution center; the segment made about 232,000 shipments into Oregon in the fiscal year ended June 30, 2026, of which Edgepark accounted for roughly 19,500, and Oregon was about 1.5 percent of segment revenue. AdaptHealth has 11,472 full-time equivalents nationally and 65 in Oregon, served roughly 27,500 unique Oregon patients and filled about 55,000 orders across 37 product categories in the twelve months to July 31, 2026, from supply stores in Salem and Medford and warehouses in Eugene, Portland and Hillsboro. Oregon revenue in dollars is redacted for both parties, as are the parties' estimated shares of the roughly 5.4 million U.S. CGM users the filing takes from Dexcom's May 2026 investor day; the parties argue the category is fragmented enough, with DME suppliers, broadline distributors and more than 60,000 community pharmacies all able to stock CGM pharmacy SKUs, that the combination raises no competitive concern.

What the business earns

Because AdaptHealth is public, the financials of the asset being sold are unusually visible. Its 2025 Form 10-K, which the Oregon filing attaches as an exhibit, reports Diabetes Health net revenue of $660.0 million in 2023, $614.4 million in 2024 and $592.4 million in 2025, and segment adjusted EBITDA of $79.6 million, $60.5 million and $26.1 million over the same three years. AdaptHealth took a $128.0 million goodwill impairment in the fourth quarter of 2025, all of it attributed to the Diabetes Health reporting unit. The 10-K's risk factors describe why: payors have been moving CGM coverage from the medical benefit to the pharmacy benefit, which routes patients to pharmacies and PBMs rather than DME suppliers, and CMS's 2026 rule restores Medicare competitive bidding with Class II CGMs and insulin pumps included, with a bundled monthly rental payment for contracts awarded in 2027 and effective no later than January 1, 2028.

Since the agreement, AdaptHealth has reported the segment as discontinued operations. Income from discontinued operations, net of tax, was $14.3 million in the third quarter of 2026 and $34.6 million for the nine months; assets held for sale stood at $177.1 million at September 30. On its second quarter call management said about $40 million of 2026 adjusted EBITDA moved into discontinued operations and that a significant portion of the sale proceeds would go to debt reduction; long-term debt was $1.87 billion at the end of the third quarter. The November 3 release says the sale is "on track to close in early 2027, subject to certain regulatory approvals," which matches the February 1 date in Oregon.

Set against those figures, the $235 million price is a fraction of what the segment's 2023 earnings would have supported, and it says as much about where CGM distribution economics have gone as about either party. Scope's valuation database carries the price alongside the reported segment revenue and EBITDA.

Cardinal's at-home build-out

The Oregon filing's list of Cardinal's relevant prior transactions traces the strategy: Liberty Medical's diabetic supply business in July 2017 ($82.4 million), Medtronic's Patient Recovery business the same month ($6.1 billion), Advanced Diabetes Supply Group from Court Square Capital Partners on April 1, 2025 ($1.05 billion in the filing; Cardinal's announcement said about $1.1 billion) and Strive Medical, the NMS Capital-backed urology supplier, on August 3, 2026 for $125 million. Cardinal's July 20 announcement presented AdaptHealth Diabetes and Strive together as "two tuck-in acquisitions" totaling approximately $360 million in cash, and said that in the year since the ADS purchase it had migrated all ADS volume to its at-Home Solutions network and added nearly 500,000 new customers. Cardinal's Other segment, which houses at-Home Solutions with Nuclear and OptiFreight, grew revenue 26 percent to $6.8 billion in the fiscal year ended June 30, 2026, with segment profit up 37 percent to $707 million; the company guided to 11 to 13 percent revenue growth and 15 to 18 percent profit growth for the segment in fiscal 2027, including both tuck-ins. Cardinal reports its first fiscal 2027 quarter on November 5.

Rob Schlissberg, who runs at-Home Solutions, told HME News in July that ADSG now serves about 500,000 people a year and that Cardinal was "leaning in" to the next round of Medicare competitive bidding, which covers both CGMs and urology supplies, rather than avoiding it. That is the mirror image of AdaptHealth's reasoning: the same reimbursement change that made the diabetes segment a drag for a $3.2 billion HME company looks like a scale opportunity to a distributor with a $6.8 billion segment to absorb it.

Scope's database records the July announcement under both targets, and the ADS and Strive transactions before it. On the seller's side it holds 36 AdaptHealth acquisitions since the start of 2019, including the five that assembled the diabetes business now being sold: Solara Medical Supplies (May 2020), Diabetes Supply Center of the Midlands (August 2020), Pinnacle Medical Solutions (October 2020), Diabetes Management & Supply (December 2020) and Healthy Living Medical Supply (June 2021). The buying stopped almost entirely after May 2022; the only additions since are WellSpan's DME business in May 2025 and Gammie HomeCare in February 2026, and in between AdaptHealth sold certain home infusion assets in June 2025.

What to watch

The Oregon preliminary review, which can end in approval, approval with conditions or referral to a comprehensive review; the Massachusetts HPC and Indiana notices, neither of which has produced a public posting yet; any New York filing; and whether Cardinal's November 5 results move the closing date. On the AdaptHealth side, the fourth quarter report should show how much of the $60 million of stranded corporate overhead the company has removed and where the proceeds go.

Sources: Oregon Health Authority, HCMO transaction 097, Edgepark - AdaptHealth (https://www.oregon.gov/oha/HPA/HP/Pages/097-edgepark-adapthealth.aspx), including the HCMO-1 notice (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/097-notice.pdf), transaction summary (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/097-transaction-summary.pdf) and Exhibit 12-1, Cardinal relevant transactions (https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/097-Cardinal-Relevant-Transactions-Summary.pdf); Cardinal Health release, July 20, 2026 (https://www.prnewswire.com/news-releases/cardinal-health-expands-home-care-business-with-two-tuck-in-acquisitions-302829980.html); AdaptHealth release, July 20, 2026 (https://secure.businesswire.com/news/home/20260720553562/en/AdaptHealth-Corp.-Enters-into-Definitive-Agreement-to-Divest-Diabetes-Health-Business-to-Cardinal-Health); AdaptHealth Form 10-K for 2025 (https://www.sec.gov/Archives/edgar/data/1725255/000162828026011213/ahco-20251231.htm); AdaptHealth second quarter 2026 release (https://www.sec.gov/Archives/edgar/data/0001725255/000162828026052149/ahco-20260804x8k_ex991.htm) and third quarter 2026 release, November 3, 2026 (https://www.sec.gov/Archives/edgar/data/0001725255/000162828026069116/ahco-20261103x8k_ex991.htm); AdaptHealth second quarter call summary (https://www.marketbeat.com/instant-alerts/adapthealth-q2-earnings-call-highlights-2026-08-04/); Cardinal Health fiscal 2026 fourth quarter release (https://www.sec.gov/Archives/edgar/data/0000721371/000072137126000037/a26q4_x063026xex991xnewsre.htm); HME News, July 20, 2026 (https://www.hmenews.com/article/cardinal-health-leans-into-cgms-urology-supplies). Transaction history from the Scope Research healthcare M&A database.